|

Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes

RECRUITINGPhase 2Sponsored by Peking University Cancer Hospital & Institute
Actively Recruiting
PhasePhase 2
SponsorPeking University Cancer Hospital & Institute
Started2026-02-01
Est. completion2027-07-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

\[18F\]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumors

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Age \>18 years old, ECOG score 0 or 1;
2. subjects with pathologically confirmed solid tumors (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of previous solid tumors;
3. There was at least one measurable target lesion according to RECIST1.1 criteria;
4. Predicted survival time ≥12 weeks;
5. Blood routine, liver and kidney function meet the following standards: see the study protocol for specific requirements;
6. Women must be using an effective contraceptive method (effective contraception means sterilization, intrauterine hormonal devices, condoms, contraceptives/pills, abstinence, or partner's removal of the vas deferentia) during the study and for 6 months after the study; Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period;
7. Subjects can fully understand and voluntarily participate in this experiment, and sign an informed consent. Compliance was good.

Exclusion Criteria:

1. Severe abnormal liver and kidney function.
2. Pre-pregnancy, pregnant and lactating women.
3. Unable to lie flat for half an hour.
4. Refusal to be a clinical investigator.
5. Claustrophobia or other mental illness.
6. Known allergy to the investigational drug or its excipients in the study treatment; Other circumstances considered by the investigator to be inappropriate for trial participation.

Conditions7

Breast CancerCancerCervical Squamous Cell CancerGastrointestinal CancersLung CancerLung Cancer (NSCLC)Melanoma (Skin Cancer)

Interventions2

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.